Imcivree Dosage

Generic name: setmelanotide
Dosage form: injection, for subcutaneous use
Drug class: Melanocortin receptor agonists

Medically reviewed by  A Ras MD.

Recommended Adult Dosing

Dosage forms:  INJ: 10 mg per mL

Obesity, POMC deficiency-associated

[1-3 mg SC qd]

Start: 2 mg SC qd x2wk, then incr. to target 3 mg SC qd as tolerated; Info: for pts w/ variant in POMC gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 1 mg SC qd if 2 mg SC qd not tolerated; D/C if wt loss or BMI change <5% after 12-16wk

Obesity, PCSK1 deficiency-associated

[1-3 mg SC qd]

Start: 2 mg SC qd x2wk, then incr. to target 3 mg SC qd as tolerated; Info: for pts w/ variant in PCSK1 gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 1 mg SC qd if 2 mg SC qd not tolerated; D/C if wt loss or BMI change <5% after 12-16wk

Obesity, LEPR deficiency-associated

[1-3 mg SC qd]

Start: 2 mg SC qd x2wk, then incr. to target 3 mg SC qd as tolerated; Info: for pts w/ variant in LEPR gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 1 mg SC qd if 2 mg SC qd not tolerated; D/C if wt loss or BMI change <5% after 12-16wk

Obesity, Bardet-Beidl syndrome-associated

[1-3 mg SC qd]

Start: 2 mg SC qd x2wk, then incr. to target 3 mg SC qd as tolerated; Info: may decr. dose to 1 mg SC qd if 2 mg SC qd not tolerated; D/C if wt loss or BMI change <5% after 1y

Renal dosing

eGFR 15-29: start 0.5 mg qd x2wk, then 1 mg qd x1wk, then incr. to target 1.5 mg qd as tolerated; eGFR <15: avoid use; Info: D/C if 0.5 mg qd not tolerated

HD/PD: not defined

Hepatic dosing

[not defined]

Recommended Peds Dosing

Dosage forms:  INJ: 10 mg per mL

Obesity, POMC deficiency-associated

[6-11 yo]

Dose: 0.5-3 mg SC qd; Start: 1 mg SC qd x2wk, then incr. by 1 mg/day to target 3 mg SC qd as tolerated; Info: for pts w/ variant in POMC gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 0.5 mg SC qd if 1 mg SC qd not tolerated; D/C if wt loss or BMI change <5% after 12-16wk

[12 yo and older]

Dose: 1-3 mg SC qd; Start: 2 mg SC qd x2wk, then incr. to target 3 mg SC qd as tolerated; Info: for pts w/ variant in POMC gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 1 mg SC qd if 2 mg SC qd not tolerated; D/C if wt loss or BMI change <5% after 12-16wk

Obesity, PCSK1 deficiency-associated

[6-11 yo]

Dose: 0.5-3 mg SC qd; Start: 1 mg SC qd x2wk, then incr. by 1 mg/day to target 3 mg SC qd as tolerated; Info: for pts w/ variant in PCSK1 gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 0.5 mg SC qd if 1 mg SC qd not tolerated; D/C if wt loss or BMI change <5% after 12-16wk

[12 yo and older]

Dose: 1-3 mg SC qd; Start: 2 mg SC qd x2wk, then incr. to target 3 mg SC qd as tolerated; Info: for pts w/ variant in PCSK1 gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 1 mg SC qd if 2 mg SC qd not tolerated; D/C if wt loss or BMI change <5% after 12-16wk

Obesity, LEPR deficiency-associated

[6-11 yo]

Dose: 0.5-3 mg SC qd; Start: 1 mg SC qd x2wk, then incr. by 1 mg/day to target 3 mg SC qd as tolerated; Info: for pts w/ variant in LEPR gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 0.5 mg SC qd if 1 mg SC qd not tolerated; D/C if wt loss or BMI change <5% after 12-16wk

[12 yo and older]

Dose: 1-3 mg SC qd; Start: 2 mg SC qd x2wk, then incr. to target 3 mg SC qd as tolerated; Info: for pts w/ variant in LEPR gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 1 mg SC qd if 2 mg SC qd not tolerated; D/C if wt loss or BMI change <5% after 12-16wk

Obesity, Bardet-Beidl syndrome-associated

[6-11 yo]

Dose: 0.5-3 mg SC qd; Start: 1 mg SC qd x2wk, then incr. by 1 mg/day to target 3 mg SC qd as tolerated; Info: may decr. dose to 0.5 mg SC qd if 1 mg SC qd not tolerated; D/C if wt loss or BMI change <5% after 1y

[12 yo and older]

Dose: 1-3 mg SC qd; Start: 2 mg SC qd x2wk, then incr. to target 3 mg SC qd as tolerated; Info: may decr. dose to 1 mg SC qd if 2 mg SC qd not tolerated; D/C if wt loss or BMI change <5% after 1y

Renal dosing

[6-11 yo]

eGFR <30: avoid use

HD/PD: not defined

[12 yo and older]

eGFR 15-29: start 0.5 mg qd x2wk, then 1 mg qd x1wk, then incr. to target 1.5 mg qd as tolerated; eGFR <15: avoid use; Info: D/C if 0.5 mg qd not tolerated

HD/PD: not defined

Hepatic dosing

[not defined]

 

SRC: NLM .